Sep 2026· i Medicina· pp.
101294
· 0 citations· 54 references
Medicine
TL;DR
A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.
Abstract
Background
Steatotic liver disease (SLD) is closely associated with cardiometabolic factors, but whether the cardiovascular-kidney-metabolic (CKM) stage stratifies risk for major adverse cardiovascular events (MACEs) and liver-related events (LREs) across SLD subtypes remains unclear.
Methods
In the UK Biobank study, participants with SLD were classified into subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-related liver disease (ALD). The primary outcomes were incident MACEs and LREs, assessed overall and by subtype. Associations were evaluated using Cox models, Kaplan-Meier curves, and population-attributable risks (PARs).
Findings
Over 14.7 years of follow-up, 17,973 MACEs (14.0%) and 2,742 LREs (2.0%) occurred among 142,564 individuals with SLD. Higher CKM stage was associated with graded increases in both outcomes (CKM stages 2-4 vs. 0-1: adjusted HRs 1.51 [95% CI 1.43-1.59] to 3.62 [3.31-3.97] for MACEs and 1.28 [1.11-1.48] to 2.32 [1.95-2.75] for LREs), with similar trends across subtypes. Obesity and hypertension were the leading contributors to both outcomes (PARs of up to 19.0% and 22.8% for LREs), whereas diabetes contributed more prominently to LREs than to MACEs (17.5% vs. 7.9%).
Conclusions
A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum. Obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.
Funding
Supported by the National Science and Technology Major Project, the National Key R&D Program of China, and the National Natural Science Foundation of China.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a systemic disorder associated with cardiovascular, renal, and metabolic comorbidities. We evaluated cardiovascular disease (CVD), four-domain cardiovascular–renal–hepatic–metabolic (CRHM) involvement, and their associations with non-invasive liver-rel...
K. Stefanaki, Dimitrios S. Karagiannakis, Maria Manolakopoulou et al.· Endocrine· 0 citations
AIM
Although steatotic liver disease (SLD) has been associated with chronic kidney disease (CKD), it remains unclear whether CKD-related outcomes are driven by hepatic steatosis itself or by accompanying cardiometabolic abnormalities. We investigated the relative contribution of hepatic steatosis and cardiometabolic ri...
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, yet the contribution of autonomic dysfunction to its progression remains incompletely understood. Pheochromocytoma and paraganglioma (PPGL), characterised by excessive catecholamine production,...
A. Henney, A. S. Davison, U. Alam et al.· European Journal of Endocrin...· 0 citations
Advanced CKM syndrome is associated with long-term mortality outcomes including all-cause and cardiovascular death, underscoring the importance of early screening and staging of CKM syndrome to prevent disease progression and reduce mortality risk.
Lan-Lan Li, D. T. Lui, C. Fong et al.· Journal of the American Hear...· 0 citations
Objective: Advanced fibrosis is the best predictor of future severe liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Our study aims to determine the association between cardiovascular disease (CVD) with time to a high-risk Fibrosis-4 Index (FIB-4) in patients with low-ri...
Myra Quiroga, K. Anderson, Jing-Wen Zhang et al.· Livers· 0 citations